Sanofi unveiled a plan to build a $1 billion manufacturing site in Beijing while completing construction at a plant in ...
Sanofi has announced plans to invest approximately €1bn to build a new insulin production base in China.
Sanofi CEO Paul Hudson says, "AI is a huge opportunity, and we can't be deniers." Mount Kanlaon Erupts, Sending Ash Cloud 3,000 Meters High in Philippines - TaiwanPlus News There are many ways to get ...
Innovations in rare blood disorders took center stage at the 2024 American Society of Hematology (ASH) Annual Meeting & ...
ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patientsNew analysis from the IMROZ phase 3 ...
New data from three oral presentations, which demonstrated significant clinical benefit with Sarclisa-based quadruplets in newly diagnosed multiple myeloma (NDMM) patients were featured at the 66th ...
After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi and Regeneron's Dupixent (dupilumab) for COPD - as has China's National ...
November 2024 has seen a variety of biotech deals take place to advance therapies across different stages in development.
This will be Sanofi's fourth production-and-supply base in China and represents its largest single investment in the country to date. Sanofi Chief Executive Paul Hudson noted that the new production ...
Sanofi has said it plans to start discussions ... while remibrutinib is in phase 3 for relapsing MS. China's InnoCare was partnering with Biogen on the development of orelabrutinib, which is ...